Denali recruits Genentech vet Carole Ho as CMO

Carole Ho

The Genentech vets behind South San Francisco-based Denali Therapeutics have recruited one of their former colleagues to join them as CMO and head of development. Carole Ho, former VP of early clinical development at Genentech, was tapped for the job. Denali turned heads a few months ago when it announced a whopping $217 million round to back their work on neurodegenerative diseases. Release

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.